المؤلفون: Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Arain, Mustafa A., Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey A., Cooper, Harry S., Deming, Dustin A., Garrido-Laguna, Ignacio, Grem, Jean L., Hoffe, Sarah E., Hubbard, Joleen, Hunt, Steven, Kamel, Ahmed, Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcah, Mary F., Nurkin, Steven, Overman, Michael J., Parikh, Aparna, Patel, Hitendra, Pedersen, Katrina S., Saltz, Leonard B., Schneider, Charles, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Johnson-Chilla, Alyse, Gregory, Kristina M., Gurski, Lisa A.

المصدر: J Natl Compr Canc Netw

مصطلحات موضوعية: Diagnosis, Differential, Treatment Outcome, Risk Factors, Intestinal Neoplasms, Intestine, Small, Practice Guidelines as Topic, Humans, Survivorship, Adenocarcinoma, Watchful Waiting, Combined Modality Therapy, Article, Neoplasm Staging

الوصف: Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::65aaef32130e230980dff17a2b9d7e8dTest
https://europepmc.org/articles/PMC10191182Test/

المؤلفون: Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Cederquist, Lynette, Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey, Cooper, Harry S., Deming, Dustin, Engstrom, Paul F., Garrido-Laguna, Ignacio, Grem, Jean L., Grothey, Axel, Hochster, Howard S., Hoffe, Sarah, Hunt, Steven, Kamel, Ahmed, Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcahy, Mary F., Murphy, James D., Nurkin, Steven, Saltz, Leonard, Sharma, Sunil, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Wuthrick, Evan, Gregory, Kristina M., Freedman-Cass, Deborah A.

المصدر: J Natl Compr Canc Netw

مصطلحات موضوعية: Colonic Neoplasms, Humans, Article

الوصف: The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation–positive metastatic colorectal cancer with regimens containing vemurafenib.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::a5e3a74dbb377fc59dcc0f0b25b5d478Test
https://europepmc.org/articles/PMC10184502Test/